A randomized phase 2 study of neratinib with or without fulvestrant for patients with HER2-positive, estrogen receptor-positive metastatic breast cancer
Stefania Morganti,Xiangying Chu,Tarah J. Ballinger,Nisha Unni,Sarah Sinclair,Robert Wesolowski,Alyssa Pereslete,Paulina Lange,Nabihah Tayob,Nancy U. Lin,José Pablo Leone,Ian E. Krop,Sara M. Tolaney,Heather A. Parsons